Bignell GR, Greenman CD, Davies H, et al. Signatures of mutation and selection in the cancer genome. Nature. 2010;463:893–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ohta M, Inoue H, Cotticelli MG, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 1996;84:587–97.
Article
CAS
PubMed
Google Scholar
Pichiorri F, Palumbo T, Suh SS, et al. Fhit tumor suppressor: guardian of the preneoplastic genome. Future Oncol. 2008;4:815–24.
Article
CAS
PubMed
PubMed Central
Google Scholar
Waters CE, Saldivar JC, Hosseini SA, Huebner K. The FHIT gene product: tumor suppressor and genome “caretaker”. Cell Mol Life Sci. 2014;71:4577–87.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434:907–13.
Article
CAS
PubMed
Google Scholar
Bartkova J, Horejsí Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864–70.
Article
CAS
PubMed
Google Scholar
Sard L, Accornero P, Tornielli S, et al. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci U S A. 1999;96:8489–92.
Article
CAS
PubMed
PubMed Central
Google Scholar
Joannes A, Grelet S, Duca L, et al. Fhit regulates EMT targets through an EGFR/Src/ERK/slug signaling axis in human bronchial cells. Mol Cancer Res. 2014;12:775–83.
Article
CAS
PubMed
Google Scholar
Suh SS, Yoo JY, Cui R, et al. FHIT suppresses epithelial-mesenchymal transition (EMT) and metastasis in lung cancer through modulation of microRNAs. PLoS Genet. 2014;10:e1004652.
Article
PubMed
PubMed Central
Google Scholar
Ottey M, Han SY, Druck T, et al. Fhit-deficient normal and cancer cells are mitomycin C and UVC resistant. Br J Cancer. 2004;91:1669–77.
Article
CAS
PubMed
PubMed Central
Google Scholar
Okumura H, Ishii H, Pichiorri F, Croce CM, Mori M, Huebner K. Fragile gene product, Fhit, in oxidative and replicative stress responses. Cancer Sci. 2009;100:1145–50.
Article
CAS
PubMed
Google Scholar
Barnes LD, Garrison PN, Siprashvili Z, et al. Fhit, a putative tumor suppressor in humans, is a dinucleoside 5′,5″’-P1, P3-triphosphate hydrolase. Biochemistry. 1996;35:11529–35.
Article
CAS
PubMed
Google Scholar
Murphy GA, Halliday D, McLennan AG. The Fhit tumor suppressor protein regulates the intracellular concentration of diadenosine triphosphate but not diadenosine tetraphosphate. Cancer Res. 2000;60:2342–4.
CAS
PubMed
Google Scholar
Taverniti V, Seraphin B. Elimination of cap structures generated by mRNA decay involves the new scavenger mRNA decapping enzyme Aph1/FHIT together with DcpS. Nucleic Acids Res. 2014;43:482–92.
Article
PubMed
PubMed Central
Google Scholar
Li Y, Kiledjian M. Regulation of mRNA decapping. Wiley Interdiscip Rev RNA. 2010;1:253–65.
Article
PubMed
Google Scholar
Draganescu A, Hodawadekar SC, Gee KR, Brenner C. Fhit-nucleotide specificity probed with novel fluorescent and fluorogenic substrates. J Biol Chem. 2000;275:4555–60.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pelletier J, Graff J, Ruggero D, Sonenberg N. Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. Cancer Res. 2015;75:250–63.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sendoel A, Dunn JG, Rodriguez EH, et al. Translation from unconventional 5′ start sites drives tumour initiation. Nature. 2017;541:494–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sozzi G, Pastorino U, Moiraghi L, et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res. 1998;58:5032–7.
CAS
PubMed
Google Scholar
Saldivar JC, Miuma S, Bene J, et al. Initiation of genome instability and preneoplastic processes through loss of Fhit expression. PLoS Genet. 2012;8:e1003077.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kiss DL, Waters CE, Ouda IM, et al. Identification of Fhit as a post-transcriptional effector of thymidine kinase 1 expression. Biochim Biophys Acta. 2017;1860:374–82.
Article
CAS
PubMed
Google Scholar
Druck T, Hadaczek P, TB F, et al. Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res. 1997;57:504–12.
CAS
PubMed
Google Scholar
Ingolia NT, Brar GA, Rouskin S, McGeachy AM, Weissman JS. The ribosome profiling strategy for monitoring translation in vivo by deep sequencing of ribosome-protected mRNA fragments. Nat Protoc. 2012;7:1534–50.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhong Y, Karaletsos T, Drewe P, et al. RiboDiff: detecting changes of mRNA translation efficiency from ribosome footprints. Bioinformatics. 2017;33:139–41.
Article
PubMed
Google Scholar
Balakrishnan R, Oman K, Shoji S, Bundschuh R, Fredrick K. The conserved GTPase LepA contributes mainly to translation initiation in Escherichia Coli. Nucleic Acids Res. 2014;42:13370–83.
Article
CAS
PubMed
PubMed Central
Google Scholar
Song Y, Sun B, Hao L, et al. Elevated eukaryotic elongation factor 2 expression is involved in proliferation and invasion of lung squamous cell carcinoma. Oncotarget. 2016;7:58470–82.
Article
PubMed
PubMed Central
Google Scholar
Human protein atlas. https://www.proteinatlas.org. Accessed December 1, 2017.
Uhlén M, Björling E, Agaton C, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics. 2005;4:1920–32.
Article
PubMed
Google Scholar
Tillotson R, Selfridge J, Koerner MV, et al. Radically truncated MeCP2 rescues Rett syndrome-like neurological defects. Nature. 2017;550:398–401.
Article
CAS
PubMed
Google Scholar
Oji Y, Tatsumi N, Fukuda M, et al. The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers. Int J Oncol. 2014;44:1461–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Palam LR, Baird TD, Wek RC. Phosphorylation of eIF2 facilitates ribosomal bypass of an inhibitory upstream ORF to enhance CHOP translation. J Biol Chem. 2011;286:10939–49.
Article
CAS
PubMed
PubMed Central
Google Scholar
Barbosa C, Romão L. Translation of the human erythropoietin transcript is regulated by an upstream open reading frame in response to hypoxia. RNA. 2014;20:594–608.
Article
CAS
PubMed
PubMed Central
Google Scholar
Domaschenz R, Kurscheid S, Nekrasov M, Han S, Tremethick DJ. The Histone variant H2A.Z is a master regulator of the epithelial-Mesenchymal transition. Cell Rep. 2017;21:943–52.
Article
CAS
PubMed
Google Scholar
Hinnebusch AG, Ivanov IP, Sonenberg N. Translational control by 5′-untranslated regions of eukaryotic mRNAs. Science. 2016;352:1413–6.
Article
CAS
PubMed
Google Scholar
Kwon SC, Yi H, Eichelbaum K, et al. The RNA-binding protein repertoire of embryonic stem cells. Nat Struct Mol Biolf. 2013;20:1122–30.
Article
CAS
Google Scholar
Castello A, Fischer B, Eichelbaum K, et al. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell. 2012;149:1393–406.
Article
CAS
PubMed
Google Scholar
Castello A, Fischer B, Frese CK et al. Comprehensive identification of RNA-binding domains in human cells. Mol cell. 2016.
Google Scholar
Siprashvili Z, Sozzi G, Barnes LD, et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci U S A. 1997;94:13771–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pace HC, Garrison PN, Robinson AK, et al. Genetic, biochemical, and crystallographic characterization of Fhit-substrate complexes as the active signaling form of Fhit. Proc Natl Acad Sci U S A. 1998;95:5484–9.
Article
CAS
PubMed
PubMed Central
Google Scholar